- Key facts & figures
- Sanofi share
- News & publications
- Events & presentations
- Corporate governance
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- US investors
- Regulated information in France
Investor Relations Awards
- Media Releases
- Our sites
- Corporate events
- Press events
- Access to healthcare
- Image Library
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Our company
- R&D innovation
- Our Products
- Our approach
- Improving access to healthcare
- Working together
- Acting ethically
- Preserving the environment
Ensuring sustainable growth
Key facts & figures
Sanofi is an integrated global healthcare company focused on patient needs. Our business includes pharmaceuticals (prescription drugs, consumer healthcare and generics), vaccines and animal health.
The creation of growth platforms and the evolution of our R&D pipeline have effectively transformed Sanofi into a major biopharmaceutical player.
FY 2014 Net Sales
+4.9% at constant exchange rates
+2.5% on a reported basis
FY 2014 Business EPS
+7.3% at constant exchange rates
+3.0% on a reported basis
Growth Platforms in 2014
+10.7% at constant exchange rates
Accounted for 76.4% of total sales in 2014
Emerging Markets: Sanofi is the #1 healthcare company in Emerging Markets with a broad product portfolio adapted to local needs.
Diabetes Solutions: Lantus®, our basal insulin, is the world’s leading diabetes brand.
Human Vaccines: Sanofi Pasteur offers a broad range of vaccines against 20 serious diseases and is the undisputed leader in flu vaccines.
Consumer Healthcare (CHC): Sanofi is the world's 3rd largest CHC player.
Animal Health: Merial is a global leader in Animal Health with expertise in both veterinary pharmaceutical products and vaccines.
Other Innovative Products: On February 5, 2015, the R&D portfolio included 43 projects, 14 of which were in Phase III or had been submitted for approval.
|FY 2014 sales||Growth at CER|
|Other Innovative Products***||€815m||+14.7%|
* Excluding Generics in Brazil, Emerging Markets grew +6.5% in FY 2014 at CER
**Some products recorded in prescription pharmaceuticals in 2013 were transferred as Consumer Healthcare products and totaled €273m in FY 2013. When excluding this category change, sales of Consumer Healthcare grew +6.8% in FY 2014 at CER
***Products launched since 2009 which are not included in the Growth Platforms listed above: Multaq®, Jevtana®, Auvi-Q™, Mozobil® and Zaltrap®
New interpretation of tax levies - applicable as from January 1st, 2014
Amended Accounting Standard on Employee Benefits (IAS19R) applicable as from January 1st, 2013